Alternative Data for Organon & Co.
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 139 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 137,000 | Sign up | Sign up | Sign up |
| Employee Rating | 78 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 20 | Sign up | Sign up | Sign up |
| Facebook Followers | 3,291 | Sign up | Sign up | Sign up |
| Instagram Followers | 8,977 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,420 | Sign up | Sign up | Sign up |
| X Followers | 713 | Sign up | Sign up | Sign up |
| X Mentions | 20 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 503 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Lobbying Cost | $93,000 | Sign up | Sign up | Sign up |
| Business Outlook | 54 | Sign up | Sign up | Sign up |
| Linkedin Employees | 7,378 | Sign up | Sign up | Sign up |
About Organon & Co.
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Its two operating segments are the Organon Products segment and the Merck Retained Products segment. It operates in the United States, China, Japan, Korea, and countries in Europe.
| Price | $8.21 |
| Target Price | Sign up |
| Volume | 4,020,000 |
| Market Cap | $2.13B |
| Year Range | $6.32 - $10.98 |
| Dividend Yield | 7.41% |
| PE Ratio | 4.3 |
| Analyst Rating | 43% buy |
| Earnings Date | February 12 '26 |
| Industry | Drug Manufacturers |
In the news
Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: ReportJanuary 22 - Yahoo Entertainment |
|
 |
Alvotech: Why FDA Delays Don't Break The Bull CaseJanuary 21 - SeekingAlpha |
 |
XPH: Healthcare Dashboard For JanuaryJanuary 15 - SeekingAlpha |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 1.6B | 745M | 857M | 160M | 460M | 1.010 |
| Q2 '25 | 1.59B | 720M | 874M | 145M | 449M | 1.000 |
| Q1 '25 | 1.51B | 672M | 841M | 87M | 325M | 1.020 |
| Q4 '24 | 1.59B | 696M | 896M | 109M | 341M | 0.900 |
| Q3 '24 | 1.58B | 659M | 923M | 359M | 402M | 0.870 |
Insider Transactions View All
| COX CARRIE SMITH filed to buy 77,869 shares at $7.7. November 13 '25 |
| COX CARRIE SMITH filed to buy 12,469 shares at $8.1. May 15 '25 |
| Falcione Aaron filed to buy 62,974 shares at $8.8. May 7 '25 |
| Karp Daniel filed to buy 46,669 shares at $8.2. May 7 '25 |
| Weaver Kirke filed to buy 52,489 shares at $9.2. May 7 '25 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$239.99 0% | 55 |
 |
Eli Lilly and CompanyLLY |
$1058.18 0% | 76 |
 |
PfizerPFE |
$27.22 0% | 57 |
 |
AstrazenecaAZN |
$193.21 0% | 61 |
 |
AbbVieABBV |
$223.43 0% | 54 |
Read more about Organon & Co. (OGN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
FAQ - Organon & Co.
The Market Cap of Organon & Co. is $2.13B.
As of today, Organon & Co.'s PE (Price to Earnings) ratio is 4.3.
Organon & Co. will report its next earnings on February 12 '26.
Currently, the price of one share of Organon & Co. stock is $8.21.
The OGN stock price chart above provides a comprehensive visual representation of Organon & Co.'s stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Organon & Co. shares. Our platform offers an up-to-date OGN stock price chart, along with technical data analysis and alternative data insights.
Yes, Organon & Co. (OGN) offers dividends to its shareholders, with a dividend yield of 7.41%. This dividend yield represents Organon & Co.'s commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Organon & Co. in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
Some of the similar stocks of Organon & Co. are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
